Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psoriasis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psoriasis
    Fumaric Acid Ester Safe and Effective Against Psoriasis in Patients Receiving Medication for Comorbidities: Presented at EADV - (DGDispatch)
    Infliximab More Effective Than Methotrexate in Patients With Moderate to Severe Plaque Psoriasis: Presented at EADV - (DGDispatch)
    Patients With Psoriasis Experience Improved Quality of Life Following Adalimumab Treatment: Presented at EADV - (DGDispatch)
    Adalimumab Yields Fast and Sustainable Scalp and Nail Results in Patients With Psoriasis: Presented at EADV - (DGDispatch)
    Comorbidities of Psoriasis Create Higher Healthcare Costs: Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Psoriasis
    • Using Biologics to Improve Both Physical and Social Function in Rheumatic Diseases
    • Rheumatic Diseases: Using Anti-TNF-alpha Agents to Improve Everyday Patient Function
    • Management of Psoriasis: Update for the Pharmacist
      Exploring Psoriatic Arthritis: Bridging Dermatology and Rheumatology
      Moderate-to-Severe Psoriasis and Psoriatic Arthritis: Reducing the Clinical and Economic Burden Through Effective Treatment Protocols

      Webcasts/CME archive

       Recent cases - Psoriasis
        Therapeutic Effect of Hyperbaric Oxygen in Psoriasis Vulgaris: Two Case Reports and a Review of the Literature
        Exacerbation of Psoriasis with beta-Blocker Therapy
        Concomitant Xeroderma Pigmentosum and Disseminated Small Plaque Psoriasis - The First Case of an Antinomic Association: A Case Report
        Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
        Pulmonary Sarcoidosis Associated with Psoriasis Vulgaris: Coincidental Occurrence or Causal Association? Case Report

        Cases archive
          




        my personal edition > psoriasis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Trial Demonstrates Safety and Efficacy of Infliximab in Psoriatic Arthritis: Presented at AAD

        By Alison Palkhivala

        SAN FRANCISCO, CA -- March 24, 2003 -- Infliximab is effective, safe and well tolerated when used for the treatment of psoriatic arthritis that does not respond to disease-modifying anti-rheumatic drug (DMARD) therapy.

        The agent can be taken with or without DMARD therapy, according to results presented here March 22nd at the 61st Annual Meeting of the American Academy of Dermatology.

        Christian Antoni, MD, from the department of medicine II in Erlangen, Germany, and colleagues from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) study group randomised 102 patients with psoriatic arthritis with peripheral polyarticular arthritis to one of two treatment groups.

        Group 1 received placebo infusions at weeks 0, 2, 6 and 24 followed by 5 mg/kg infliximab at weeks 16, 18, 22, 30, 38 and 46. Group 2 received 5 mg/kg infliximab infusions at weeks 0, 2, 6 and 14 followed by placebo infusions at weeks 16 and 18, followed again by infliximab infusions at weeks 22, 30, 38 and 46.

        All patients in this multicentre trial had active disease and had unsuccessful treatment with at least one DMARD prior to study entry. They were permitted to use up to 10 mg/day of corticosteroids as well as DMARDs and nonsteroidal anti-inflammatory drugs (NSAIDs) at stable doses during the trial.

        The trial included a 4 month, blinded, placebo-controlled phase followed by an 8 month open-label phase.

        By week 16, infliximab successfully reduced the signs and symptoms of psoriasis, as judged by Psoriasis Area and Severity Index (PASI) score. Specifically, among patients with PASI scores over 2.5 at the beginning of the trial, those on placebo experienced an increase to a mean of 9.29, while those taking infliximab had a decrease to a mean of 1.61.

        By week 50, mean PASI scores was 1.76 in the infliximab-treated patients, which represented an 81% reduction from baseline. Overall, 67% of infliximab-treated patients had a 75%% response on the PASI, compared with none in the placebo group (P<0.0001).

        With respect to arthritis symptoms, by week 16, 69% of those taking infliximab versus only 8% of those on placebo (p<0.001) experienced an American College of Rheumatology (ACR) 20 response. In addition, 49% of infliximab-treated patients achieved ACR 50 criteria, and 29% achieved ACR 70 criteria. None of the placebo patients met these criteria (P < 0.0001).

        Overall, infliximab was well tolerated, with the most commonly seen adverse events in both groups being cold symptoms, flu and/or cough. Serious adverse events included one patient who had a stroke, one who had a joint infection and one who had a fall and meningioma while taking infliximab. Serious adverse events in the placebo group included a suspected myocardial infarction and an injection site reaction. No cases of tuberculosis or opportunistic infections were seen.

        The authors concluded that, "infliximab therapy with or without DMARDs is effective in treatment of [psoriatic arthritis]." The agent reduces synovitis, as assessed by ACR criteria, psoriatic lesions, as assessed by PASI, and was safe and well tolerated, they said.


        [Study title: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Abstract P9]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send